Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Successful preparation of mitoxantrone emulsion containing non-ionic contrast medium]W Ichikawa, Z Nihei, S Sawai, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1997
[Combination therapy with 5'-DFUR, MMC and CDDP in patient with far advanced gastric cancer: report of a case]H Tomita, H Fukunari, M Shibata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1994
[Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma]W Ichikawa, S Togo, T Osanai, et al.
The Tokushima Journal of Experimental Medicine|December 1, 1996
The role of cell-associated interleukin-1 in bleomycin-induced pulmonary fibrosisK Asada, F Ogushi, K Tani, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 15, 1998
[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]W Ichikawa, T Osanai, C Shimizu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2009
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areasK Fujita, W Ichikawa, W Yamamoto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2015
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)K Tanabe, M Fujii, K Nishikawa, et al.
Investigational New Drugs|December 16, 2014
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancerMasato Matsuyama, H Ishii, J Furuse, et al.
ESMO Open|May 7, 2025
Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13ARK Ouchi, Y Sunakawa, A Tsuji, et al.
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
Pageof 5